Proximity increases opportunities for relationship building, which leads to trust and more business. Further, there are certain activities such as projects that require close interaction with client scientists and/or involve intellectual property protection issues that are best carried out when close to the client's research and development (R&D) operations.
In the past two years, several India-based contractors have stepped up to acquire European and North American bases of operations, sometimes paying a considerable premium for the privilege. These include companies such as Nicholas Piramal (Mumbai), which bought operations from Avecia and Pfizer in the United Kingdom; Dishman Pharmaceuticals and Chemicals (Ahmedabad), which bought Carbogen and Amcis in Switzerland; and Jubilant Organosys (Noida), which acquired injectables manufacturer Hollister-Stier Laboratories in the US.Those companies are about to be joined by Shanghai-based WuXi PharmaTech, which announced plans in late December to acquire AppTec Laboratory Services, Inc. (St. Paul, MN) for $162.7 million. AppTec, which has 495 employees, provides manufacturing and laboratory services to the biopharmaceutical and medical device industries. The company also provides clinical-scale cell culture manufacturing at its Philadelphia facility, where it has a 2500 L bioreactor train and a number of Wave bioreactors.
AppTec's growth has been nothing short of phenomenal. Revenues for 2007 of $71 million were up 40% from $51 million in 2006 and more than three times 2004 revenues of $23 million. Most of that growth has been organic and has come from the biopharmaceutical sector.
WuXi's story has been striking as well, as it has emerged as a major player in chemistry-based discovery, process development, and manufacturing services since 2002. Its 2007 revenues of $133 million were double its 2006 revenues and almost eight times its 2004 revenues of $21 million. In 2007, WuXi successfully completed an initial public offering (IPO) on the New York Stock Exchange, raising $155 million. It has 2700 employees, including 2100 scientists and claims most major pharmaceutical companies as clients.
Building very large-scale facilities has been a key part of WuXi's strategy. Its facilities include a 630,000-ft2 discovery chemistry laboratory, a 220,000-ft2 process development and manufacturing facility in Shanghai, and a 130,000-ft2 chemical manufacturing facility in Tianjin. It is building a 267,000-ft2 preclinical toxicology facility in Suzhou, China, a bold move to expand its service offerings beyond chemistry and leap ahead of preclinical market leaders Covance (Princeton, NJ) and Charles River Laboratories (Wilmington, MA) in terms of China-based preclinical capacity.
The aggressive moves by WuXi PharmaTech, Jubilant Organosys, Nicholas Piramal, and other Asian pharmaceutical services providers stand out in contrast to Western competitors who have been in the business much longer and would seem to have more resources and stronger pharmaceutical company relationships to draw on. Thus far, only a few Western companies, notably Albany Molecular Research, Aptuit (Greenwich, CT), and Lonza (Basel, Switzerland), have taken the plunge to set up wholly owned chemistry and development operations in Asia.